Impact of biosimilars in psoriasis treatment.
نویسندگان
چکیده
1. Serviço de Dermatologia. Centro Hospitalar do Porto. Porto. Portugal. 2. Instituto de Ciências Biomédicas Abel Salazar. Universidade do Porto. Porto. Portugal. 3. Consulta de Psoríase. Serviço de Dermatologia. Centro Hospitalar Lisboa Norte. Lisboa. Portugal. 4. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. 5. Unidade de Investigação em Dermatologia. Instituto de Medicina Molecular. Universidade de Lisboa. Lisboa. Portugal. Recebido: 18 de Novembro de 2013 Aceite: 05 de Dezembro de 2013 | Copyright © Ordem dos Médicos 2013 Tiago TORRES1,2, Paulo FILIPE3,4,5, Manuela SELORES1,2 Acta Med Port 2013 Nov-Dec;26(6):646-648
منابع مشابه
Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
Latin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while maintaining the safety and efficacy profile of their branded innovator comparators. To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Counc...
متن کاملBiosimilars and Reference Biologics: Decisions on Biosimilar Interchangeability Require the Involvement of Dermatologists Biosimilares y biológicos de referencia: la intercambiabilidad de los biosimilares requiere la participación del dermatólogo
On September 13, 2013, the European Medicines Agency (EMA) approved the first biosimilar and treatment of moderate to severe psoriasis will be one of the indications. Undoubtedly this important news for dermatologists will have a major impact on prescribing patterns and management of patients with moderate to severe psoriasis. On June 27, 2013, the Committee for Medicinal Products for Human Use...
متن کاملBiopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.
The entry of biosimilar forms of biopharmaceutical therapies for the treatment of psoriasis and other immune-mediated disorders has provoked considerable interest. Although dermatologists are accustomed to the use of a wide range of generic topical agents, recognition of key differences between original agent (ie, the name brand) and the generic or biosimilar agent is necessary to support optim...
متن کاملBiosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies).
Biosimilars represent a new trend in the treatment of many immune-mediated inflammatory diseases. Regulatory requirements for approval of biosimilars are different from those of originators and rely mostly on the evidence generated from bioequivalence studies and in particular from RCTs. Our goal in this review was to search for relevant studies from randomized controlled trials on the biosimil...
متن کاملThe use of biosimilar drugs in psoriasis: a position paper.
-The development of biologic therapy has substantially improved the treatment of psoriasis and psoriatic arthritis. At the same time, the elevated cost of biologics has prompted debate on the economic sustainability of the public health system. -As patents expire for biologics, business interests and the high capacity of today’s biotechnology industry have encouraged laboratories to develop new...
متن کاملBiosimilars in Dermatology: Current Situation (Part I).
The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more biosimilars can be expected to follow in the coming months and years. Logically, this new situation will have economic repercussions and alter prescribing patterns among dermatologists. In this article, we review regulatory issues related to the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Acta medica portuguesa
دوره 26 6 شماره
صفحات -
تاریخ انتشار 2013